pdp1

Migration, Crosslink

📖

pdp1

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-pdp1

📖 Wiki Page

gene2997 wordssynced 2026-04-02

pdp1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">PDP1 — Pyruvate Dehydrogenase Phosphatase 1</th></tr>
<tr><td><b>Gene Symbol</b></td><td>PDP1</td></tr>
<tr><td><b>Full Name</b></td><td>Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 1</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>8q22.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[5407](https://www.ncbi.nlm.nih.gov/gene/5407)</td></tr>
<tr><td><b>OMIM ID</b></td><td>[605857](https://omim.org/entry/605857)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>[ENSG00000153540](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153540)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9N2I8](https://www.uniprot.org/uniprot/Q9N2I8)</td></tr>
<tr><td><b>Protein Type</b></td><td>Ser/Thr protein phosphatase</td></tr>
<tr><td><b>Expression</b></td><td>Brain (high), heart, skeletal muscle, liver</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></td>
</tr>
</table>
</div>

Overview

...

pdp1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">PDP1 — Pyruvate Dehydrogenase Phosphatase 1</th></tr>
<tr><td><b>Gene Symbol</b></td><td>PDP1</td></tr>
<tr><td><b>Full Name</b></td><td>Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 1</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>8q22.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[5407](https://www.ncbi.nlm.nih.gov/gene/5407)</td></tr>
<tr><td><b>OMIM ID</b></td><td>[605857](https://omim.org/entry/605857)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>[ENSG00000153540](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153540)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9N2I8](https://www.uniprot.org/uniprot/Q9N2I8)</td></tr>
<tr><td><b>Protein Type</b></td><td>Ser/Thr protein phosphatase</td></tr>
<tr><td><b>Expression</b></td><td>Brain (high), heart, skeletal muscle, liver</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></td>
</tr>
</table>
</div>

Overview

PDP1 encodes the catalytic subunit of pyruvate dehydrogenase phosphatase (PDP), a critical mitochondrial enzyme that activates the pyruvate dehydrogenase complex (PDC) by removing inhibitory phosphate groups from the E1-alpha subunit. This enzymatic activation is essential for glucose metabolism in all aerobic cells, but is particularly critical for neurons given their high and continuous energy demands for synaptic function, action potential propagation, and cellular maintenance[@zhang2023].

The pyruvate dehydrogenase complex is one of the central metabolic enzymes connecting glycolysis to the citric acid cycle (Krebs cycle). Located in the mitochondrial matrix, PDC catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA, generating NADH in the process. This reaction is irreversible and represents a critical regulatory point in cellular metabolism. The activity of PDC is tightly regulated through phosphorylation/dephosphorylation: phosphorylation of the E1-alpha subunit (PDHA1) at specific serine residues (Ser293 and Ser232) inhibits the complex, while dephosphorylation by PDP1 activates it[@zhang2023].

Mutations in PDP1 cause mitochondrial pyruvate dehydrogenase deficiency, a severe metabolic disorder characterized by impaired glucose oxidation, lactic acidosis, and progressive neurodegeneration leading to Leigh syndrome or severe developmental encephalopathy[@holm2022][@gandhi2020]. Beyond these rare genetic disorders, emerging evidence implicates PDP1 dysfunction in the pathogenesis of more common neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), where impaired glucose metabolism and mitochondrial dysfunction are established hallmarks[@shearer2018][@hubbard2019][@yang2021].

Gene and Protein Structure

Gene Organization

The PDP1 gene is located on chromosome 8q22.1 and spans approximately 24 kb. It consists of 19 exons encoding a protein of 625 amino acids with a molecular weight of approximately 71 kDa. The gene is expressed ubiquitously with highest levels in tissues with high metabolic demand: brain, heart, skeletal muscle, and liver.

Protein Domain Architecture

The PDP1 protein contains several functional domains:

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal regulatory domain | 1-200 | Substrate binding, regulatory interactions |
| Phosphatase catalytic domain | 201-400 | Ser/Thr phosphatase activity |
| C-terminal dimerization domain | 401-625 | Enzyme dimerization, stability |

The catalytic domain contains the conserved GDxHG motif and GDxVDRG sequences characteristic of the protein phosphatase 2C (PP2C) family. PDP1 requires magnesium or manganese ions as cofactors for catalytic activity, and its function is modulated by several allosteric regulators including calcium, ADP, and NADH[@jeong2020].

PDP1 belongs to the PP2C family of magnesium-dependent protein phosphatases. Two related proteins exist in humans:

PDP2 (Pyruvate Dehydrogenase Phosphatase 2): A catalytically inactive regulatory subunit that can form heterodimers with PDP1
PDP1L1: A testis-specific isoform with distinct regulatory properties

The functional significance of these isoforms and their roles in different tissues remain areas of active investigation[@lara2021].

Normal Function in Neurons

Metabolic Integration

In neurons, PDP1 plays a central role in integrating glucose metabolism with cellular energetics:

Glucose uptake and glycolysis: Neurons primarily use glucose as their main metabolic substrate, importing it through glucose transporters (primarily GLUT3 in neurons)

Pyruvate production: Glycolysis generates pyruvate in the cytoplasm, which is imported into mitochondria

PDC activation: PDP1 dephosphorylates PDHA1 to activate PDC, enabling conversion of pyruvate to acetyl-CoA

Citric acid cycle: Acetyl-CoA enters the citric acid cycle, generating NADH and FADH2 for oxidative phosphorylation

ATP production: The electron transport chain produces ATP through oxidative phosphorylation

This metabolic pathway is essential for meeting the high energy demands of neuronal function. A single action potential can consume significant ATP, and the restoration of ionic gradients requires substantial energy input. Synaptic vesicle recycling, neurotransmitter release, and postsynaptic signal transduction all require continuous ATP supply.

Regulation by Neuronal Activity

Neural activity directly modulates PDP1 function through multiple mechanisms[@fecher2019]:

Calcium signaling: Activity-induced calcium influx can activate calmodulin-dependent pathways that influence PDP1
Metabolic feedback: ATP/ADP ratios, NADH/NAD+ ratios, and pyruvate levels all affect PDC activity
Transcriptional regulation: Neuronal activity can regulate PDP1 expression through CREB and other activity-dependent transcription factors

This metabolic regulation provides a link between neuronal activity and energy metabolism, ensuring that ATP production matches demand.

Mitochondrial Dynamics

PDP1 function is intertwined with mitochondrial health[@tieu2021]:

Mitochondrial morphology: Functional mitochondria are essential for PDC activity
Mitochondrial trafficking: Energy-demanding regions like synapses require local mitochondrial ATP production
Mitochondrial quality control: Mitophagy and mitochondrial biogenesis affect overall metabolic capacity

Role in Neurodegeneration

Alzheimer's Disease

PDP1 dysfunction is strongly implicated in [Alzheimer's disease](/diseases/alzheimers-disease)[@chen2023][@cheng2019]:

Metabolic Deficits in AD

Multiple studies have documented reduced PDC activity in AD brain:

Post-mortem studies: AD brains show significantly reduced PDH activity in affected regions (temporal cortex, hippocampus)
PET imaging: Reduced glucose metabolism in AD brains correlates with clinical severity (hypometabolism is an early biomarker)
Animal models: Transgenic AD mouse models show early PDH dysfunction before amyloid deposition

Mechanisms of PDP1 Dysfunction in AD

Several mechanisms contribute to PDP1 dysfunction in AD:

Tau pathology: Hyperphosphorylated tau disrupts mitochondrial function and PDH expression

Amyloid-beta effects: Aβ oligomers directly impair mitochondrial respiration and PDH activity

Oxidative stress: Chronic oxidative damage affects PDP1 protein function

Transcriptional dysregulation: Reduced PDP1 gene expression in AD brain

Thiamine deficiency: Thiamine (vitamin B1) is an essential cofactor for PDC; AD patients often show thiamine deficiency

Therapeutic Implications for AD

Targeting PDP1 and the PDC represents a promising therapeutic approach for AD:

PDK inhibitors: Pyruvate dehydrogenase kinase (PDK) inhibitors can prevent inhibitory phosphorylation of PDHA1, effectively activating PDC
Thiamine supplementation: Benfotiamine (lipid-soluble thiamine derivative) has shown promise in clinical trials
Dichloroacetate (DCA): This PDK inhibitor has been tested in AD and shown some cognitive benefits in pilot studies
Ketone body supplementation: Provides alternative fuel that bypasses the PDC defect

Parkinson's Disease

PDP1 is particularly relevant to [Parkinson's disease](/diseases/parkinsons-disease) given the high energy demands of dopaminergic neurons[@edwards2023][@yang2021][@kim2023]:

Energy Demands of Dopaminergic Neurons

Dopaminergic neurons in the substantia nigra pars compacta (SNc) have exceptionally high metabolic requirements:

Continuous pacemaking activity requires sustained ATP supply
Long axonal projections to the striatum require extensive mitochondrial support
High iron content makes these neurons susceptible to oxidative stress
Dopamine metabolism generates reactive oxygen species

PDP1 Dysfunction in PD

Reduced PDH activity: Post-mortem studies show decreased PDH activity in PD substantia nigra
Mitochondrial complex I deficiency: PD is associated with complex I dysfunction; impaired PDC compounds this
Metabolic inflexibility: PD neurons cannot adequately compensate for metabolic stress
Alpha-synuclein toxicity: Impaired PDP1 compounds energy deficit

Leigh Syndrome

Mutations in PDP1 cause classic Leigh syndrome (subacute necrotizing encephalomyelopathy)[@gomez2024][@holm2022][@stacpoole2017]:

Clinical Features

Onset: Typically in infancy or early childhood
Progressive neurodegeneration: Developmental regression, movement disorders, seizures
Metabolic crisis: Episodes of lactic acidosis, typically triggered by illness
Brain lesions: Bilateral lesions in basal ganglia, brainstem, and thalamus

Biochemical Hallmarks

Elevated lactate and pyruvate in blood and CSF
Severely reduced PDC activity in patient fibroblasts/muscle
Normal or near-normal PDH levels but most is in phosphorylated (inactive) form

Treatment Approaches

Ketogenic diet: Providing alternative fuel (ketone bodies) that bypasses the PDH defect
Dichloroacetate (DCA): Inhibits PDK to increase PDH activation; shows clinical benefit in some patients
Thiamine supplementation: High-dose thiamine in responsive patients

Expression Patterns

Brain Regional Expression

PDP1 exhibits region-specific expression in the brain:

| Region | Expression Level | Significance |
|--------|-----------------|--------------|
| [Hippocampus](/brain-regions/hippocampus) | Very high | Memory processing |
| [Cerebral Cortex](/brain-regions/cortex) | High | Cognitive functions |
| [Cerebellum](/brain-regions/cerebellum) | High | Motor coordination |
| [Substantia Nigra](/brain-regions/substantia-nigra) | High | PD vulnerability |
| [Basal Ganglia](/brain-regions/basal-ganglia) | High | Movement control |

Cell-Type Specificity

Within the brain, PDP1 is expressed in:

Neurons: All neuronal subtypes; highest in highly metabolic neurons
Astrocytes: Metabolic support functions
Oligodendrocytes: Myelin production energy demands
Microglia: Lower expression; inflammation can modulate

Therapeutic Implications

Drug Development Targets

Modulating PDP1 activity represents a therapeutic strategy for neurodegeneration[@jha2021][@fernandez2022]:

Direct Targets

PDP1 activators: Small molecules that enhance PDP1 catalytic activity
PDK inhibitors: Prevent inhibitory phosphorylation (e.g., dichloroacetate, AZD7545)
Allosteric modulators: Compounds that enhance PDP1 regulatory sensitivity

Upstream Targets

Thiamine (B1): Essential cofactor; supplementation benefits thiamine-deficient patients
Glucose transporters: Enhancing neuronal glucose uptake
Mitochondrial biogenesis: PGC-1α activators to increase mitochondrial mass

Metabolic Bypass Strategies

For conditions where PDP1 function is severely impaired:

Ketone bodies: β-hydroxybutyrate supplementation bypasses PDC defect
Pyruvate supplementation: Provides alternative substrate
Tricarballylate derivatives: Novel metabolic intermediates

Biomarker Potential

PDP1 as a biomarker:

PDH activity ratio: Phosphorylated/total PDH as metabolic status indicator
CSF biomarkers: PDP1 fragments in cerebrospinal fluid
Imaging: PET tracers for glucose metabolism as indirect PDP1 function

Interaction Network

Metabolic Pathways

PDP1 interfaces with several critical metabolic pathways:

Mermaid diagram (expand to render)

Key Protein Interactions

| Interactor | Relationship | Function |
|------------|--------------|----------|
| PDHA1 | Substrate | Deposphorylation target |
| PDK1 | Regulatory kinase | Phosphorylates PDHA1 |
| PDK2 | Regulatory kinase | Phosphorylates PDHA1 |
| PDP2 | Regulatory subunit | Modulates activity |
| DLD | E3 component | Part of PDC complex |
| DLAT | E2 component | Part of PDC complex |

Animal Models

Knockout Studies

Pdps1 knockout mice: embryonic lethal
Conditional knockouts: metabolic dysfunction
Brain-specific deletion: neurodegeneration phenotype

Transgenic Models

PDP1 overexpression: Enhanced metabolic capacity
PDK overexpression: Reduced PDC activity
Mutant PDP1: Dominant-negative effects

Summary

PDP1 (Pyruvate Dehydrogenase Phosphatase 1) is a critical mitochondrial enzyme that regulates the pyruvate dehydrogenase complex, the gatekeeper for glucose oxidation in aerobic metabolism. Through its dephosphorylation of the PDHA1 subunit, PDP1 directly controls the conversion of pyruvate to acetyl-CoA, linking glycolysis to the citric acid cycle and oxidative phosphorylation.

In neurons, where energy demands are exceptionally high, PDP1 function is essential for synaptic transmission, axonal transport, and overall cellular viability. PDP1 dysfunction contributes to the pathogenesis of major neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, where impaired glucose metabolism and mitochondrial dysfunction are established hallmarks.

Therapeutic strategies targeting PDP1 and the broader pyruvate dehydrogenase complex—including PDK inhibitors, thiamine supplementation, and metabolic modulators—represent promising approaches for treating these devastating disorders. Understanding the precise role of PDP1 in disease progression and identifying patient subgroups who might benefit from metabolic interventions remain important goals for future research.

Protein Structure and Biochemistry

Catalytic Mechanism

PDP1 belongs to the protein phosphatase 2C (PP2C) family, which catalyzes the removal of phosphate groups from serine and threonine residues through a metal-dependent mechanism:

Metal ion coordination: Two magnesium ions coordinate the catalytic water molecule

Phosphate binding: The substrate phosphate binds to active site residues

Catalytic attack: Activated water attacks the phosphoester bond

Product release: Dephosphorylated protein and phosphate are released

The GDxHG and GDxVDRG motifs in the catalytic domain coordinate the essential magnesium ions required for phosphatase activity.

Structural Domains

| Domain | Amino Acids | Function |
|--------|-------------|----------|
| N-terminal dimerization arm | 1-50 | Enables PDP1 dimer formation |
| Regulatory domain | 51-180 | Allosteric regulation, substrate recognition |
| Catalytic core | 181-450 | Ser/Thr phosphatase activity |
| C-terminal tail | 451-625 | Regulatory phosphorylation sites |

Isoforms and Variants

Human PDP1 exists as multiple isoforms:

Isoform 1 (canonical): 625 amino acids, full-length catalytic subunit
Isoform 2: Alternative start site, N-terminally truncated
Isoform 3: Alternative splicing, missing exon 12

Metabolic Integration

Glucose Metabolism in the Brain

The brain relies almost exclusively on glucose oxidation for energy, making PDC function critical:

Glucose uptake: GLUT1 (blood-brain barrier) and GLUT3 (neurons) mediate glucose entry

Glycolysis: Cytoplasmic glucose → pyruvate, net 2 ATP

Pyruvate import: Mitochondrial pyruvate carrier imports pyruvate

PDC conversion: Pyruvate → acetyl-CoA + NADH (PDC)

Citric acid cycle: Acetyl-CoA → CO2 + NADH + FADH2

Oxidative phosphorylation: NADH/FADH2 → ATP

Regional Vulnerability

Different brain regions show varying PDC activity:

| Region | PDH Activity | Vulnerability |
|--------|--------------|---------------|
| Hippocampus CA1 | High | Early AD changes |
| Cerebral cortex layer 5 | High | AD tau pathology |
| Substantia nigra | Moderate | PD dopaminergic loss |
| Cerebellum | High | Less affected in AD |

Disease Mechanisms

Alzheimer's Disease Pathogenesis

PDC dysfunction contributes to AD through multiple mechanisms:

Energy Crisis:

Reduced glucose metabolism precedes clinical symptoms
Hypometabolism detected by FDG-PET correlates with cognitive decline
PDH activity reduction in AD brain tissue

Amyloid Interaction:

Aβ oligomers directly inhibit PDH function
Amyloid deposition impairs mitochondrial function
Energy deficit exacerbates amyloid processing

Tau Relationship:

Hyperphosphorylated tau disrupts mitochondrial trafficking
Energy deprivation promotes tau pathology
Vicious cycle between metabolism and tau

Therapeutic Implications:

PDK inhibitors (dichloroacetate) show cognitive benefits
Thiamine supplementation improves PDH activity
Ketogenic diets bypass PDH defect

Parkinson's Disease Connections

Dopaminergic neurons have particularly high energy demands:

Metabolic Demands:

Continuous autonomous pacemaking requires sustained ATP
Long axonal projections to striatum
High iron content promotes oxidative stress

PDH Alterations in PD:

Reduced PDH activity in substantia nigra
Complex I inhibition compounds PDH deficit
Alpha-synuclein impacts mitochondrial function

Therapeutic Approaches:

Dichloroacetate improves PDH activity in models
CoQ10 supports mitochondrial function
PGC-1α activators increase mitochondrial mass

Leigh Syndrome

PDP1 deficiency causes classic Leigh syndrome:

Clinical Features:

Onset typically in first year of life
Developmental regression, hypotonia
Ataxia, dystonia, seizures
Episodes of metabolic crisis

Biochemical Hallmarks:

Elevated lactate and pyruvate
Reduced PDH activity in fibroblasts
Most PDH in phosphorylated (inactive) form

Treatment Strategies:

Ketogenic diet (ketone bodies bypass PDH)
Dichloroacetate (PDK inhibition)
Thiamine (cofactor supplementation)
Supportive care for metabolic crises

Regulation and Signaling

Allosteric Regulation

PDP1 activity is modulated by multiple metabolites:

| Regulator | Effect | Mechanism |
|-----------|--------|-----------|
| ADP | Activation | Allosteric activator |
| ATP | Inhibition | Competitive with ADP |
| NADH | Inhibition | Product inhibition |
| Ca²⁺ | Activation | Calmodulin-dependent |
| Mg²⁺ | Required | Catalytic cofactor |

Post-Translational Regulation

PDP1 is itself regulated by phosphorylation:

Phosphorylation by PDK: PDK can phosphorylate PDP1, reducing its activity
Oxidative modification: ROS can inactivate PDP1
Proteolytic cleavage: Generates truncated active forms

Transcriptional Control

PDP1 expression is regulated by:

PGC-1α: Mitochondrial biogenesis driver
CREB: Activity-dependent expression
FOXO transcription factors: Metabolic stress response

Interaction Networks

Metabolic Pathway Connections

Mermaid diagram (expand to render)

Protein-Protein Interactions

| Interactor | Interaction Type | Functional Consequence |
|------------|------------------|----------------------|
| PDHA1 | Substrate | Dephosphorylation target |
| PDK1/2/3 | Kinase | Phosphorylates PDHA1 |
| PDP2 | Regulatory | Forms heterodimer |
| DLD | Structural | Part of PDC complex |
| DLAT | Structural | E2 component of PDC |
| DBT | Structural | E2 component of PDC |
| Lipoate | Cofactor | Essential for PDC function |

Therapeutic Strategies

Current Pharmacological Approaches

PDK Inhibitors:

Dichloroacetate (DCA): Most studied, improves PDH activity
AZD7545: More specific PDK2 inhibitor
Novel compounds: In development for neurodegenerative diseases

Metabolic Cofactors:

Thiamine (B1): Essential cofactor, often deficient in AD
Benfotiamine: Lipid-soluble thiamine derivative
Lipoic acid: Mitochondrial cofactor
CoQ10: Electron transport chain support

Alternative Energy Sources:

Ketone bodies: Bypass PDH defect
Triheptanoin: Odd-chain fatty acid
DAG derivatives: Novel metabolic intermediates

Emerging Therapies

Gene Therapy:

AAV-mediated PDP1 delivery
CRISPR-based PDP1 activation
Mitochondrial-targeted expression

Small Molecule Activators:

Direct PDP1 activators
Allosteric modulators
Protein-protein interaction inhibitors

Combination Approaches

Rationale for combination therapy:

PDH activation + antioxidant: Protect from oxidative damage

Metabolic + neurotrophic: Support both energy and survival

Multiple metabolic targets: Redundancy ensures effect

Research Models

Cell Culture Models

Primary neurons: Metabolic studies in neurons
iPSC-derived neurons: Patient-specific models
Neuroblastoma cells: Easily cultured, metabolic manipulation
Mouse embryonic fibroblasts: Control and disease comparisons

Animal Models

Genetic Models:

PDP1 knockout mice (embryonic lethal)
Brain-specific knockouts (viable, neurodegeneration)
Conditional knockouts (temporal control)

Disease Models:

Transgenic AD models with PDH alterations
MPTP/6-OHDA PD models
Leigh syndrome models

Human Studies

Post-mortem brain tissue analysis
Patient-derived fibroblasts
PET imaging of glucose metabolism
CSF biomarker measurements

Biomarker Development

Diagnostic Biomarkers

PDH-related markers:

PDH activity ratio (phosphorylated/total)
PDP1 protein levels in CSF
Lipoate derivatives as markers

Metabolic markers:

Lactate/pyruvate ratio
Glucose metabolism (FDG-PET)
ATP/ADP ratios

Prognostic Biomarkers

Baseline PDH activity predicts progression
PDH response to treatment
Metabolic reserve capacity

Therapeutic Biomarkers

Target engagement markers
PDH activation pharmacodynamics
Metabolic endpoint measures

Prevention and Risk Modification

Lifestyle Factors

Protective Factors:

Regular exercise (enhances PDH activity)
Ketogenic diet (bypasses PDH)
Thiamine-rich diet

Risk Factors:

Thiamine deficiency
Chronic hyperglycemia
Sedentary lifestyle

Environmental Considerations

Alcohol (impairs PDH function)
Certain medications (metformin affects PDC)
Heavy metal exposure (mitochondrial toxicity)

Future Directions

Knowledge Gaps

Cell-type specific PDP1 functions in brain

Dynamic changes during disease progression

Optimal biomarker combinations

Patient stratification for metabolic therapy

Research Priorities

Develop brain-penetrant PDK inhibitors
Identify direct PDP1 activators
Validate biomarker assays in large cohorts
Understand metabolic resilience factors

External Links

[NCBI Gene: PDP1](https://www.ncbi.nlm.nih.gov/gene/5407)
[UniProt: PDP1](https://www.uniprot.org/uniprot/Q9N2I8)
[Ensembl: PDP1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153540)
[OMIM: PDP1](https://omim.org/entry/605857)
[GTEx Portal: PDP1](https://gtexportal.org/home/gene/PDP1)

📖 View canonical wiki page →

Related Entities

PDP1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-pdp1
kg_node_id	PDP1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-788406c477dd
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-pdp1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

5%

Debates

0

Incoming

1

Outgoing

6

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

pdp1

pdp1

Overview

pdp1

Overview

Gene and Protein Structure

Gene Organization

Protein Domain Architecture

Isoforms and Related Proteins

Normal Function in Neurons

Metabolic Integration

Regulation by Neuronal Activity

Mitochondrial Dynamics

Role in Neurodegeneration

Alzheimer's Disease

Metabolic Deficits in AD

Mechanisms of PDP1 Dysfunction in AD

Therapeutic Implications for AD

Parkinson's Disease

Energy Demands of Dopaminergic Neurons

PDP1 Dysfunction in PD

Leigh Syndrome

Clinical Features

Biochemical Hallmarks

Treatment Approaches

Expression Patterns

Brain Regional Expression

Cell-Type Specificity

Therapeutic Implications

Drug Development Targets

Direct Targets

Upstream Targets

Metabolic Bypass Strategies

Biomarker Potential

Interaction Network

Metabolic Pathways

Key Protein Interactions

Animal Models

Knockout Studies

Transgenic Models

Summary

See Also

Protein Structure and Biochemistry

Catalytic Mechanism

Structural Domains

Isoforms and Variants

Metabolic Integration

Glucose Metabolism in the Brain

Regional Vulnerability

Disease Mechanisms

Alzheimer's Disease Pathogenesis

Parkinson's Disease Connections

Leigh Syndrome

Regulation and Signaling

Allosteric Regulation

Post-Translational Regulation

Transcriptional Control

Interaction Networks

Metabolic Pathway Connections

Protein-Protein Interactions

Therapeutic Strategies

Current Pharmacological Approaches

Emerging Therapies

Combination Approaches

Research Models

Cell Culture Models

Animal Models

Human Studies

Biomarker Development

Diagnostic Biomarkers

Prognostic Biomarkers

Therapeutic Biomarkers

Prevention and Risk Modification

Lifestyle Factors

Environmental Considerations

Future Directions

Knowledge Gaps

Research Priorities

External Links